A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Phase 1

• Conditions: Advanced Solid Tumor
• Interventions: Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

• Registration Number: NCT04719065
• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Brief Summary

This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in subjects with advanced solid tumor.

Detailed Description

This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in subjects with advanced solid tumor. 90 subjects will be recruited. The first 60 subjects will be randomly assigned into 2 groups, group A and group B. The 30 subjects in group A will receive the Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 28 days (q4w, 1 cycle). The 30 subjects in group B will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, every 21 days (q3w, 1 cycle). After this, the last 30 subjects will be assigned into group B. All subjects will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or subject decision (a maximum of 8 cycles). Delays in drug administration is allowed from cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after cycle 2 is permitted, and the minimum dose is 12 mg/m2.

Study Timeline

• Study First Submitted: 2020-12-14
• Study Start: 2021-01-13
• Study First Submitted QC: 2021-01-19
• Study First Posted: 2021-01-22
• Status Verified: 2021-08
• Last Update Submitted: 2021-10-28
• Last Update Posted: 2021-11-01
• Primary Completion: 2022-04-13
• Study Completion: 2024-04-13

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;
2. Age ≥18, without gender limitation;
3. Histologically and/or cytologically confirmed diagnosis of unresectable local or metastasizing advanced solid tumor;
4. Fail to respond to standard therapy or lack of effective treatment, including no standard therapy, intolerance of standard therapy, etc.;
5. At least one measurable lesion according to RECIST v1.1;
6. ECOG performance status of 0 or 1;
7. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation);
8. Adequate organ function;
9. Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrollment;
10. Fully comply with the protocol.

Exclusion Criteria

1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;
2. Untreated or symptomatic central nervous system (CNS) metastases;
3. CTCAE Grade 3 or Grade 4 gastrointestinal hemorrhage within 12 weeks prior to the first dose administration;
4. History of allotransplantation;
5. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;
6. Serious infection or interstitial pneumonia within 1 week prior to the first dose administration;
7. Use of other anticancer treatment within 4 weeks prior to the first dose administration;
8. Enrolled in any other clinical trials within 4 weeks prior to the first dose administration;
9. Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period;
10. Thrombosis or thromboembolism within 6 months prior to screening;
11. History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ;
12. Impaired cardiac function or serious cardiac disease;
13. Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2;
14. Life expectancy<12 weeks;
15. Pregnant or lactating female;
16. Serious and/or uncontrolled systemic diseases;
17. Not suitable for this study as decided by the investigator due to other reasons.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A, Mitoxantrone Hydrochloride Liposome Injection, q4w	Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)	Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
Group B, Mitoxantrone Hydrochloride Liposome Injection, q3w	Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)	Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.

Primary Outcome Measures

Name	Time	Method
adverse events (AEs)	from the first dose injection to 28 days after the last dose injection, assessed up to 36 weeks	The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).

Secondary Outcome Measures

Name	Time	Method
duration of response (DoR)	From the enrollment to CR,PR, PD, death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy
duration of complete response (DCR)	From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)	To investigate the preliminary antitumor efficacy
overall response rate (ORR)	From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)	To investigate the preliminary antitumor efficacy
progression-free survival (PFS)	From the enrollment to CR,PR, PD, death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy
overall survival (OS)	From the enrollment to CR, PR, PD, death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy
maximum time (Tmax)	Cycle 1 to cycle 4, approximately 16 weeks	To investigate PK characteristics
maximum concentration (Cmax)	Cycle 1 to cycle 4, approximately 16 weeks	To investigate PK characteristics
area under the plasma concentration-time curve from time zero to the time of last observed concentration (AUC0-t)	Cycle 1 to cycle 4, approximately 16 weeks	To investigate PK characteristics
apparent terminal half-life (t1/2)	Cycle 1 to cycle 4, approximately 16 weeks	To investigate PK characteristics

Trial Locations

Locations (8)

The First Affiliated Hospital of Bengbu Medical College; 🇨🇳 Bengbu, Anhui, China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; 🇨🇳 Guangzhou, Guangdong, China

The Affiliated Cancer Hospital of Guizhou Medical University; 🇨🇳 Guiyang, Guizhou, China

Yibin Second People's Hospital; 🇨🇳 Yibin, Sichuan, China

Tianjin Medical University Cancer Institute & Hospital; 🇨🇳 Tianjin, Tianjin, China

Affiliated Hospital of Hebei University; 🇨🇳 Baoding, Hebei, China

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China

Renmin Hospital of Wuhan University; 🇨🇳 Wuhan, Hubei, China